Table 1:

Number of men, median overall and relative survival in months, and 5-year relative survival in percentage (95% confidence interval) for men diagnosed with de novo metastatic prostate cancer (MPC) in the SEER-18 areas by grouped age (15–84) and year at diagnosis. Relative survival is presented in terms of de novo only survival.

Year	Age, y	N	Median Relative Survival (in months)	5-yr De novo Relative Survival (95% CI)	10-yr De novo Relative Survival (95% CI)
2000–2005	15–49	310	2.5	29% [24%, 34%]	20% [15%, 24%]
	50–64	2986	2.8	32% [30%, 33%]	19% [18%, 21%]
	65–74	3689	2.9	34% [32%, 36%]	18% [16%, 19%]
	75–84	4073	2.1	26% [25%, 28%]	15% [13%, 17%]
	15+	12794	2.4	29% [28%, 30%]	17% [16%, 17%]
2006–2011	15–49	349	2.7	28% [23%, 33%]	13% [9%, 17%]
	50–64	3896	3.0	34% [33%, 36%]	18% [17%, 20%]
	65–74	3826	2.9	34% [33%, 36%]	20% [18%, 22%]
	75–84	3741	2.2	28% [26%, 30%]	14% [12%, 16%]
	15+	13812	2.5	30% [30%, 31%]	16% [16%, 17%]
2012–2017	15–49	351	2.9	26% [20%, 32%]	─
	50–64	5404	3.4	35% [33%, 37%]	─
	65–74	6136	3.3	35% [33%, 37%]	─
	75–84	5002	2.5	29% [27%, 32%]	─
	15+	19855	2.9	31% [30%, 32%]	─